# ğŸ“… Daily Report - 2025-11-09

> ä»Šæ—¥ç­›é€‰å‡º **52** æ¡å†…å®¹ï¼Œæ¥è‡ª **3** ä¸ªæ¥æº

<div class="powered-by-top">Powered by <a href="https://kyplus.de">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai">Claude</a></div>

---

## ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“

### ğŸ“° å…¬ä¼—å·

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
ä¸­ç§‘é™¢æ›¾å®‰å›¢é˜Ÿæ­ç¤ºå¹¼å¹´å¿ƒè„å†ç”Ÿå…³é”®ç»†èƒï¼ˆClusterinâºå¿ƒè‚Œç»†èƒäºšç¾¤ï¼‰ï¼Œä¸ºæˆå¹´å¿ƒè„å†ç”Ÿæä¾›æ–°é¶ç‚¹ã€‚ä¸­å±±å¤§å­¦å›¢é˜Ÿå‘ç°PRODH2é€šè¿‡ä»£è°¢-è½¬å½•è°ƒæ§è½´é©±åŠ¨ä¹³è…ºç™Œéª¨è½¬ç§»ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
*   **è‚¿ç˜¤ç ”ç©¶**ï¼šæ³›ç™Œå¤šç»„å­¦åˆ†æï¼ˆå•åŸºå› ã€å•ç»†èƒã€ç©ºè½¬ã€éªŒè¯ã€ä»£è°¢ï¼‰ï¼Œè‚¿ç˜¤ç¥ç»æµ¸æ¶¦ï¼Œç™Œç—‡ç–«è‹—ï¼Œå…ç–«æ²»ç–—ï¼Œä¹³è…ºç™Œéª¨è½¬ç§»ã€‚
*   **ç¥ç»ç§‘å­¦**ï¼šè‰¾ä¼¦è„‘ç§‘å­¦ç ”ç©¶æ‰€å•ç»†èƒç ”ç©¶ã€‚
*   **åŸºç¡€ç”Ÿç‰©å­¦**ï¼šè„‚è‚ªåŠ¨å‘˜ä»£è°¢è¿‡ç¨‹ï¼Œå·¨å™¬ç»†èƒæåŒ–ä¸ä»£è°¢äº¤äº’ä½œç”¨ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
*   **å•ç»†èƒåˆ†æ**ï¼šCellHintè‡ªåŠ¨åŒ–åè°ƒæ•´åˆä¸åŒscRNA-seqæ•°æ®é›†ï¼›PRISM-GRNæ¢å¤å•ç»†èƒå¤šç»„å­¦æ•°æ®åŸºå› è°ƒæ§ç½‘ç»œï¼›Hotspotåˆ†æè¯†åˆ«åŸºå› æ¨¡å—ã€‚
*   **ç»Ÿè®¡åˆ†æ**ï¼šmetasensåŒ…å¤„ç†å«ç¼ºå¤±æ•°æ®çš„äºŒå…ƒç»“å±€Metaåˆ†æã€‚
*   **å¯è§†åŒ–**ï¼šRtsneåŒ…å®ç°t-SNEé™ç»´å¯è§†åŒ–ã€‚

### ğŸ§¬ æ•°æ®å‰æ²¿

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
å•ç»†èƒæµ‹åºæŠ€æœ¯åœ¨æ­ç¤ºç»†èƒå¼‚è´¨æ€§ã€å…ç–«ç»†èƒåˆ†åŒ–åŠç–¾ç—…æœºåˆ¶æ–¹é¢å–å¾—è¿›å±•ï¼Œå¦‚é£ŸèŸ¹çŒ´ï¼ˆRhCMVï¼‰å¯¹CCR5è®°å¿†Tç»†èƒçš„å½±å“åŠMASHè‚çº¤ç»´åŒ–è¿›å±•ä¸­çš„ä¸­æ€§ç²’ç»†èƒä½œç”¨ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- è‚¿ç˜¤è¿›å±•ä¸å¹²é¢„æœºåˆ¶ï¼šæ¢è®¨äº† Artesunate æ²»ç–—èƒ¶è´¨ç˜¤ã€EZH2 è°ƒæ§ä¹³è…ºç™Œè¿›å±•ã€UGT2B17 åœ¨å‰åˆ—è…ºç™Œä¸­çš„ä½œç”¨ã€ä»¥åŠè‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒçš„åˆ†å­ç‰¹å¾ã€‚
- ç¥ç»ç§‘å­¦ä¸é€€è¡Œæ€§ç–¾ç—…ï¼šç ”ç©¶äº† CBD çš„æŠ—ç‚ä½œç”¨åŠå…¶å¯¹ T ç»†èƒçš„å½±å“ã€ISR æŠ‘åˆ¶å‰‚å»¶é•¿ Pelizaeus-Merzbacher ç—…å°é¼ å¯¿å‘½ã€ä»¥åŠ SLC2A5 æŠ‘åˆ¶å‰‚å¯¹ç¼ºè¡€æ€§è„‘æŸä¼¤çš„ä¿æŠ¤ä½œç”¨ã€‚
- æ¤ç‰©ä¸å¾®ç”Ÿç‰©äº’ä½œï¼šåˆ†æäº†æ‹Ÿå—èŠ¥ä¸­å—ä½“æ¿€é…¶åœ¨å½¢æˆå±‚æ´»æ€§ä¸­çš„ä½œç”¨ï¼Œä»¥åŠé©¬é“ƒè–¯æ™šç–«ç—…èŒçš„è½¬å½•ç»„ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- å•ç»†èƒ RNA æµ‹åº (scRNA-seq) å’Œæ ¸ (snRNA-seq) è¢«å¹¿æ³›åº”ç”¨äºè§£æå¤æ‚ç”Ÿç‰©ç³»ç»Ÿä¸­çš„ç»†èƒç±»å‹å’ŒçŠ¶æ€ã€‚
- ç½‘ç»œè¯ç†å­¦ä¸è½¬å½•ç»„æµ‹åºçš„ç»“åˆï¼Œç”¨äºæ¢ç´¢è¯ç‰©ä½œç”¨æœºåˆ¶ã€‚

### ğŸ§ª åšå®¢æ›´æ–°

> **ä»Šæ—¥ç„¦ç‚¹**ï¼š
QIAGEN æ”¶è´­ Parse Biosciencesï¼Œæ‹“å±•å•ç»†èƒæµ‹åºæŠ€æœ¯ï¼Œèµ‹èƒ½AIè¯ç‰©ç ”å‘ã€‚

**ä¸»è¦æ–¹å‘**ï¼š
- å•ç»†èƒRNAæµ‹åºæ­ç¤ºè—çŒªå¢å¼ºçš„è„‚è‚ªç”Ÿæˆä¸è„‚è‚ªé…¸è½¬è¿æœºåˆ¶ï¼Œè§£é‡Šå…¶é«˜äº§è„‚ä¸è€å¯’æ€§ã€‚
- RNAæµ‹åºå‘ç°Dnmt1è°ƒæ§ç”Ÿé•¿æ¿è½¯éª¨ç»†èƒèƒ½é‡ä»£è°¢ï¼Œé˜æ˜éª¨ç”Ÿé•¿æ–°æœºåˆ¶ã€‚

**æŠ€æœ¯äº®ç‚¹**ï¼š
- Parse Biosciences çš„é«˜å¯æ‰©å±•æ€§ã€æ— éœ€ä»ªå™¨çš„å•ç»†èƒè§£å†³æ–¹æ¡ˆã€‚
- å•ç»†èƒRNAæµ‹åºæŠ€æœ¯åœ¨åŠ¨ç‰©è‚²ç§å’Œéª¨ç”Ÿé•¿ç ”ç©¶ä¸­çš„åº”ç”¨ã€‚

---

## ğŸ“š åˆ†ç±»æµè§ˆ

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (20æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **æœ€æ–°8.5åˆ†å•åŸºå› ç”Ÿä¿¡ï¼Œæ³›ç™Œ+å•ç»†èƒ+ç©ºè½¬+éªŒè¯ï¼Œå¤šç»„å­¦åˆ†æä¸€èµ·ä¸Šåˆ†ï¼**
- âœï¸ **ä½œè€…**ï¼šä¸œæ™“ç”Ÿç‰©
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€åŸºå› ç»„ã€ç”Ÿä¿¡
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&mid=2247492992&idx=1&sn=8c1479ceed954564fc6b243655d0f591)

**2.** â­ **CellHintè‡ªåŠ¨åŒ–åè°ƒä¸æ•´åˆä¸åŒscRNA-seqæ•°æ®é›†çš„ç»†èƒç±»å‹æ³¨é‡Š**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡èœé¸Ÿå›¢
- ğŸ·ï¸ **å…³é”®è¯**ï¼šRNA-seqã€RNAseqã€scRNA
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&mid=2247537944&idx=1&sn=f48c0cdf743d834d10f566537d4b4d20)

**3.** **è¯è¿›å›› | Natureçƒ­è®®ï¼šAIä¼šè®©ç”Ÿç‰©ä¿¡æ¯å¤±ä¸šå˜›**
- âœï¸ **ä½œè€…**ï¼šå•ç»†èƒå¤©åœ°
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç”Ÿç‰©ä¿¡æ¯ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šå¡å°”ï¼Œä½ å¥½ã€‚è¿™æ˜¯è¿æ¥å“¥ç”Ÿä¿¡å®¶ä¹¦çš„ç¬¬ä¸ƒåå››å°ã€‚ä¸€è·¨å…¥å››å­£åº¦ï¼Œæ—¶é—´å¸¦ä¸Šäº†åŠ é€Ÿå™¨ï¼Œè¿‡å¾—é£å¿«ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&mid=2247533534&idx=1&sn=eb8ec377b253ba84a163eb1ab2a44ec1)

**4.** **å…ç–«æ²»ç–—çš„æ¨åŠ¨è€…--ç™Œç—‡ç–«è‹—**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡èœé¸Ÿå›¢
- ğŸ·ï¸ **å…³é”®è¯**ï¼šç™Œç—‡ã€å…ç–«
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&mid=2247537887&idx=1&sn=c403fd0c7125dd8c2f0f139430d0d133)

**5.** **7.7åˆ†1åŒºç”Ÿä¿¡ï¼Œå…¨æ–‡32ä¸ªFigureèšç„¦æœ€æ–°çƒ­ç‚¹ï¼šè‚¿ç˜¤ç¥ç»æµ¸æ¶¦ã€‚å°ç¼–è®¤è¯çš„é«˜è´¨é‡ç”Ÿä¿¡æ–‡ç« ï¼ŒæŠ•ç¨¿åˆ°æ¥æ”¶ä»…ä¸¤ä¸ªå¤šæœˆï¼**
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡å°è¯¾å ‚
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503895&idx=2&sn=eb8f8f3c2dfcdee31af57088297d59e1)

**6.** **è‰¾ä¼¦è„‘ç§‘å­¦ç ”ç©¶æ‰€æœ€æ–°Natureï¼Œè¿™ä¸ªå•ç»†èƒåšçš„åƒæ ‘å¶ä¸€æ ·ï¼Œç”Ÿä¿¡ä»£ç å­¦ä¹ **
- âœï¸ **ä½œè€…**ï¼šç”Ÿä¿¡é’±åŒå­¦
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒã€ç”Ÿä¿¡
- ğŸ“ **æè¿°**ï¼šnatureå•ç»†èƒæ–‡ç« åˆ†æå­¦ä¹ 
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&mid=2247495452&idx=1&sn=e6286011173c2ffb544708f08884452a)

**7.** **Cell Stem Cell | ä¸­ç§‘é™¢æ›¾å®‰å›¢é˜Ÿåˆä½œæ­ç¤ºå¹¼å¹´å¿ƒè„å†ç”Ÿå…³é”®ç»†èƒï¼Œä¸ºé‡å¯æˆå¹´å¿ƒè„å†ç”Ÿæä¾›å…¨æ–°é¶ç‚¹**
- âœï¸ **ä½œè€…**ï¼šè½¬åŒ–åŒ»å­¦ç½‘
- ğŸ·ï¸ **å…³é”®è¯**ï¼šTMEã€å¿ƒè„
- ğŸ“ **æè¿°**ï¼šç ”ç©¶é‰´å®šå‡ºå¹¼å¹´å“ºä¹³åŠ¨ç‰©å¿ƒè„å†ç”Ÿè¿‡ç¨‹ä¸­å…·æœ‰æ ¸å¿ƒè°ƒæ§ä½œç”¨çš„æŸä¼¤è¯±å¯¼å‹ Clusterinâºï¼ˆCluâºï¼‰å¿ƒè‚Œç»†èƒäºšç¾¤
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&mid=2656509121&idx=3&sn=fd0573e227a5a68a810f7803fcbc5418)

**8.** **Cancer Cellï¼šåŒ—äº¬åå’ŒåŒ»å­¦é™¢è‚¿ç˜¤å­¦é¢†åŸŸæ–°è¿›å±•**
- âœï¸ **ä½œè€…**ï¼šä¸é¦™å­¦æœ¯
- ğŸ·ï¸ **å…³é”®è¯**ï¼šè‚¿ç˜¤ã€cancer
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&mid=2247649656&idx=2&sn=898cec70d05e7881d86f35a025232820)

**9.** **å•ç»†èƒhotspotåˆ†æåŸºå› æ¨¡å—è¯†åˆ«**
- âœï¸ **ä½œè€…**ï¼šå•ç»†èƒå¤©åœ°
- ğŸ·ï¸ **å…³é”®è¯**ï¼šå•ç»†èƒ
- ğŸ“ **æè¿°**ï¼šHotspotä¸»è¦æ˜¯é€šè¿‡æ„å»ºç»†èƒçš„k-æœ€è¿‘é‚»å›¾ï¼Œå¹¶åœ¨è¯¥å›¾ä¸Šè¿›è¡Œå±€éƒ¨è‡ªç›¸å…³è®¡ç®—ï¼Œä»è€Œå‘ç°ç»†èƒå­é›†ä¸­å…·æœ‰ååŒè¡¨è¾¾å…³ç³»çš„åŸºå› æ¨¡å—
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&mid=2247533549&idx=1&sn=cf340631a80c30715beecce39b1a4dde)

**10.** **è¯¦è§£ï¼šè„‚è‚ªåŠ¨å‘˜çš„ä»£è°¢è¿‡ç¨‹**
- âœï¸ **ä½œè€…**ï¼šå°æä»£è°¢
- ğŸ·ï¸ **å…³é”®è¯**ï¼šä»£è°¢
- ğŸ“ **æè¿°**ï¼šè„‚è‚ªåŠ¨å‘˜æ˜¯æœºä½“åœ¨éœ€è¦èƒ½é‡æ—¶å°†å‚¨å­˜çš„ç”˜æ²¹ä¸‰é…¯åˆ†è§£ä¸ºæ¸¸ç¦»è„‚è‚ªé…¸å’Œç”˜æ²¹å¹¶é‡Šæ”¾åˆ°è¡€æ¶²ä¸­çš„ç”Ÿç†è¿‡ç¨‹ã€‚
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&mid=2247484016&idx=1&sn=d45e8e457fe4124e23d8dd0d76907e1a)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 10 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-å…¬ä¼—å·)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (29æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰

**1.** â­ **GSE217531 åŸºäºè½¬å½•ç»„æµ‹åºå’Œç½‘ç»œè¯ç†å­¦ï¼Œæ¢ç´¢é’è’¿ç¥é…¯å¹²é¢„èƒ¶è´¨ç˜¤ç»†èƒå¹¶äº§ç”Ÿä¸åŒæ²»ç–—æ•ˆæœçš„æ½œåœ¨æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€resistanceã€TCGAã€DepMapã€depmapã€sequencingã€RNAseqã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€Visiumã€genomeã€genomicsã€transcriptomeã€proteomeã€proteomicsã€Seuratã€Scanpyã€epigeneticã€epigenomeã€histoneã€pathwayã€enrichmentã€clustering
- ğŸ“ **æè¿°**ï¼šContributors : Tao Li ; Xia Mao ; Yanqiong Zhang ; Na LinSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensArtesunate possesses the potential of intervening with glioma, however, its pharmacological mechanisms remain unclarified. In this research, we aim to explore the regulatory mechanism of artesunate acting on glioma through constructing the interaction network of therapeutic effects-related genes of artesunate based on transcriptome sequencing data of glioma cells, and then verified by apoptosis staining and molecular docking at cellular level. In vitro cell activity and proliferation assay of two human glioma cell lines indicated that artesunate exerted more obvious inhibitory effects on the cell activity and proliferation of U87 cells than that of U251 cells. It could significantly promote apoptosis in U87 cells (P0.05), detected by using Hoechst and TUNEL cell apoptosis staining. Further, the differential expression gene sets between artesunate-sensitive and non-sensitive cell line, as well the therapeutic effects-related genes of artesunate were obtained, respectively, by transcriptome sequencing and differential data analysis using the lysis buffer of U87 and U251 cells before and after artesunate treatment. Then, key putative targets that related to therapeutic effects were screened by constructing the interaction network of differential genes of three above comparison groups, and calculating their topological characteristics. Pathway enrichment analysis showed that those key putative targets were significantly enriched in several signaling pathways that were closely associated with the main pathological changes of glioma, among which ATF4-DDIT3-PARP1 signaling axis, that was related with cell apoptosis, was the most enriched in. Molecular docking indicated that artesunate had fine binding affinities with ATF4 and DDIT3. Above all, this study preliminarily revealed that artesunate may induce the apoptosis and inhibited cell proliferation of glioma cells through regulating the abnormal alterations of corresponding proteins in ATF4-DDIT3-PARP1 signaling axis, which provided the novel scientific basis for its potential application in treating glioma.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217531)

**2.** â­ **GSE303537 å¤§éº»äºŒé…šå‘æŒ¥æŠ—ç‚ä½œç”¨ï¼Œä½†ç»´æŒ T æ•ˆåº”è®°å¿†ç»†èƒåˆ†åŒ–ï¼šä¸€é¡¹äººç±»å•ç»†èƒç ”ç©¶ [scRNA-seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€resistanceã€TCGAã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€genomeã€genomicsã€bioinformaticsã€Seuratã€clustering
- ğŸ“ **æè¿°**ï¼šContributors : Michael T Eadon ; Debora L GischSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCannabidiol is widely available and often used for pain management. Individuals with kidney disease or renal allografts have limited analgesia options. We conducted a Phase 1 healthy volunteer study to compare the peripheral immune cell distribution before (pre-cannabidiol) and after exposure to cannabidiol at steady state (post-cannabidiol). This study included specimens from 12 participants who received oral cannabidiol (up to 5 mg/kg twice daily) for 12 days. Lymphocytes were isolated and stimulated with anti-CD3/CD28 antibodies, with or without tacrolimus. Understanding the clinical safety of cannabidiol use is important given the paucity of pain control options available for immunocompromised transplant populations. Each individual has three conditions that are sequenced for the phase No CD3/CD28, CD3/CD28 and CD3/CD28 +Tacrolimus across two phases: pre-CBD and post-CBD.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303537)

**3.** â­ **GSE303068 å¤§éº»äºŒé…šå‘æŒ¥æŠ—ç‚ä½œç”¨ï¼Œä½†ç»´æŒ T æ•ˆåº”è®°å¿†ç»†èƒåˆ†åŒ–ï¼šä¸€é¡¹äººç±»å•ç»†èƒç ”ç©¶ [snRNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€resistanceã€TCGAã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€genomeã€genomicsã€bioinformaticsã€Seuratã€clustering
- ğŸ“ **æè¿°**ï¼šContributors : Michael T Eadon ; Debora L GischSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCannabidiol is widely available and often used for pain management. Individuals with kidney disease or renal allografts have limited analgesia options. We conducted a Phase 1 healthy volunteer study to compare the peripheral immune cell distribution before (pre-cannabidiol) and after exposure to cannabidiol at steady state (post-cannabidiol). This study included specimens from participants who received oral cannabidiol (up to 5 mg/kg twice daily) for 12 days. Lymphocytes were isolated and stimulated with anti-CD3/CD28 antibodies, with or without tacrolimus. Understanding the clinical safety of cannabidiol use is important given the paucity of pain control options available for immunocompromised transplant populations. Each individual has three conditions that are sequenced for the phase No CD3/CD28, CD3/CD28 and CD3/CD28 +Tacrolimus across two phases: pre-CBD and post-CBD.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303068)

**4.** â­ **GSE303503 EZH2 é€šè¿‡è°ƒèŠ‚ä¸Šçš®ç»†èƒå¯å¡‘æ€§æ¥æŒ‡å¯¼ä¹³è…ºç™Œè¿›å±• [RNA-Seq]**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€TMEã€cardiacã€TCGAã€DepMapã€depmapã€RNA-seqã€RNAseqã€DNA-seqã€ChIP-seqã€ATAC-seqã€single.cellã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€Seuratã€Scanpyã€epigeneticã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Linshan Liu ; Ellie Massey ; Dongmei Zuo ; Alain Pacis ; Mert Demirdizen ; Jessica Cinkornpumin ; Yu Gu ; Elizabeth Podleszanski ; Hailey Proud ; Virginie Sanguin-Gendreau ; Vasilios Papavasiliou ; Zhengze Jiang ; Harvey W. Smith ; William Pastor ; Paolo Ceppi ; William J. MullerSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBreast cancer remains a leading cause of death among women, encompassing diverse molecular subtypes with distinct clinical outcomes. The HER2+ subtype is particularly aggressive, with many patients eventually developing resistance to HER2-targeted therapies, underscoring the urgent need for alternative treatment strategies. Enhancer of Zeste Homolog 2 (EZH2), the catalytic subunit of Polycomb Repressive Complex 2, represses the expression of genetic programs crucial for differentiation, control of proliferation, and apoptosis through histone H3 lysine 27 trimethylation (H3K27me3). To investigate the role of EZH2 in HER2+ tumor progression, we crossed a genetically engineered mouse model (GEMM) of HER2-driven breast cancer with a conditional Ezh2 knockout strain. The results showed that Ezh2 is essential for accelerating tumor initiation and metastatic dissemination in HER2-driven breast cancer. Combined bulk and single cell RNA sequencing analyses revealed a significant downregulation of basal cell populations in the absence of Ezh2, characterized by the loss of Tp63 expression, and an upregulation of luminal progenitor cell populations, driven by crucial transcription factors such as Esr1, thereby driving luminal lineage commitment. Further, inhibition of EZH2 in vitro resulted in increased expression of ER in HER2+ human breast cancer cell lines and rendered them susceptible to tamoxifen. Altogether, these findings demonstrate that EZH2 dictates breast cancer plasticity through control of cellular identity and provides rationale for combining EZH2 inhibitors with endocrine therapies to improve outcomes in HER2+ breast cancer.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303503)

**5.** â­ **GSE303581 å¤§éº»äºŒé…šå‘æŒ¥æŠ—ç‚ä½œç”¨ï¼Œä½†ç»´æŒTæ•ˆåº”è®°å¿†ç»†èƒåˆ†åŒ–ï¼šä¸€é¡¹äººä½“å•ç»†èƒç ”ç©¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€carcinomaã€immuneã€immunityã€immunologyã€TMEã€cardiacã€gliomaã€resistanceã€TCGAã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€genomeã€genomicsã€bioinformaticsã€Seuratã€clustering
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE303581)

**6.** â­ **GSE277705 ISR æŠ‘åˆ¶é€šè¿‡å¢åŠ å°‘çªèƒ¶è´¨ç»†èƒå­˜æ´»ç‡å»¶é•¿äº†ä½©åˆ©æªä¼Šæ–¯-æ¢…å°”èŒ¨å·´èµ«ç—…å°é¼ æ¨¡å‹çš„å¯¿å‘½**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€immuneã€TMEã€gliomaã€Alzheimerã€TCGAã€Hi-Cã€single.cellã€single-cellã€scRNAã€scDNAã€spatialã€genomeã€genomicsã€proteomeã€proteomicsã€Seuratã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Brian Popko ; Yanan Chen ; Rejani Kunjamma ; Karin Lin ; Caitlin Connellly ; Carmela SidrauskiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe leukodystrophy Pelizaeus-Merzbacher disease (PMD) is caused by myelin protein proteolipid protein (PLP) gene mutations. PMD is characterized by oligodendrocyte death and CNS hypomyelination; thus, increasing oligodendrocyte survival and enhancing myelination could provide therapeutic benefit. We used the PMD mouse model Jimpy to explore the impact of the integrated stress response (ISR) on the oligodendrocyte response to mutant PLP expression. Jimpy animals in which the ISR-triggering eIF2ï¡ kinase PERK is inactivated have an extended lifespan that correlates with increased oligodendrocyte survival and enhanced CNS myelination. Inactivation of the downstream components of the ISR pathway CHOP and GADD34, in contrast, did not rescue oligodendrocytes or myelin. Phosphorylated eIF2ï¡ inhibits the exchange factor eIF2B, resulting in diminished protein synthesis. Treatment with small molecule eIF2B activators 2BAct and ISRIB dramatically increased oligodendrocyte survival, CNS myelination, and doubled the lifespan of Jimpy mice. These results suggest that ISR modulation could provide therapeutic benefit to PMD patients.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277705)

**7.** â­ **GSE288522 å•ç»†èƒ (sc) RNAæµ‹åºæ­ç¤ºäº†NSGè‚¿ç˜¤æ¨¡å‹ä¸­è½¬åŸºå› MAGE-A1ç‰¹å¼‚æ€§TCR-T CD4+å’ŒCD8+ç»†èƒçš„è½¬å½•çŠ¶æ€**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€carcinomaã€TMEã€gliomaã€resistanceã€TCGAã€RNAseqã€single.cellã€single-cellã€scRNAã€scATACã€spatialã€Visiumã€genomeã€genomicsã€transcriptomeã€transcriptomicsã€epigenome
- ğŸ“ **æè¿°**ï¼šContributors : Shihong Zhang ; Tzu-Hao Tang ; Sinead Kinsella ; Francesco Mazziotta ; Lauren Martin ; Bo Lee ; Aude ChapuisSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe have studied the efficacy of MAGE-A1 specific transgenic T cells against A375F NSG model by flow cytometry and IHC analysis. We then employed a scRNAseq approach to characterize the transcriptional states of transgenic CD4+ and CD8+ TCR-T cells that infiltrated into A375F tumor by extracting these cells from tumors. This scRNAseq study allow us to compare the transcriptional differences between our groups ( T-TCR-MA1-CD8ab, T-TCR-MA1-CD8/28)
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288522)

**8.** â­ **GSE297659 äººç±»ä½“å¤–è‚¿ç˜¤ç›¸å…³å·¨å™¬ç»†èƒæ¨¡å‹çš„è¡¨å¾åŠå…¶è½¬åŒ–ç›¸å…³æ€§**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€carcinomaã€immuneã€TMEã€cardiacã€resistanceã€TCGAã€Hi-Cã€scRNAã€scDNAã€scATACã€spatialã€genomeã€genomicsã€Seuratã€histoneã€enrichment
- ğŸ“ **æè¿°**ï¼šContributors : Arthur Dyer ; Rebecca Dudley ; Shreya Ahuja ; Clara Alsinet ; Pawan Poudel ; Georgina Bowyer ; Kalvin Sahota ; Saly Songvilay ; Des Jones ; Matthew Glover ; Sonja Hess ; Elina Timosenko ; Simon J DovediSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTumour-associated macrophages (TAMs) are key components of the tumour microenvironment with a demonstrated ability to modulate anti-tumour T-cell responses and immunotherapy outcomes. With increasing realisation that the M1/M2 paradigm does not reflect the complexity of macrophage phenotypes in cancer patients, an urgent need has arisen to develop improved, translatable in vitro models for human TAMs. To address this gap, we have screened conditioned media from a panel of tumour cell lines for their ability to induce suppressive marker upregulation on human monocyte-derived macrophages (hMDMs), as well as active T-cell immunosuppression. We performed secretome characterization of these tumour-conditioned media (TCM) to shed light on cancer cell-derived soluble factors that may contribute to TAM polarisation. Furthermore, we characterized the proteomic and transcriptomic signatures of macrophages exposed to either TCM or primary ascites fluid from ovarian cancer patients and performed bioinformatics analysis to determine the most translationally relevant models of TAMs. In summary, our work provides mechanistic insights on tumour-macrophage crosstalk in the context of establishing suppressive TAM phenotypes and addresses the long-standing gap of defining translationally relevant human in vitro TAM models.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297659)

**9.** â­ **GSE308064 PAD4âº ä¸­æ€§ç²’ç»†èƒé€šè¿‡ NETs-DNA/TAOK1/MAPK é€šè·¯ä¿ƒè¿›è‚æ˜ŸçŠ¶ç»†èƒæ´»åŒ–å¹¶åŠ é€Ÿ MASH çº¤ç»´åŒ–è¿›å±•**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€TMEã€gliomaã€TCGAã€DepMapã€depmapã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€genomicsã€proteomeã€Seuratã€Scanpyã€histoneã€pathway
- ğŸ“ **æè¿°**ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensNeutrophils play a pivotal role in the progression of metabolic-associated steatohepatitis (MASH) by mediating inflammatory responses. However, the heterogeneity of neutrophil subsets in MASH and their specific contributions to disease progression remain unclear. In this study, analysis of liver biopsies from 265 patients revealed a strong association between elevated neutrophil counts and MASH severity, particularly fibrosis. Five distinct neutrophil subsets were identified in human liver tissue, with PAD4âº neutrophils serving as key drivers in MASH progression. Mechanistically, PAD4âº neutrophils generate neutrophil extracellular traps (NETs) and activate hepatic stellate cells via the TAOK1-dependent MAPK signaling pathway. Inhibition of PAD4âº neutrophils in vivo attenuated the progression of liver fibrosis without exacerbating liver injury. Collectively, these findings elucidate the pivotal involvement of PAD4âº neutrophils in MASH progression and identify them as promising therapeutic targets for mitigating fibrosis and inflammation.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308064)

**10.** â­ **GSE305815 ç‰ç±³ç°æ–‘ç—…æ—©æœŸã€ä¸­æœŸå’Œæ™šæœŸç‰ç±³å°¾å­¢èŒè½¬å½•ç»„çš„åˆ†æ**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€oncologyã€carcinomaã€TMEã€gliomaã€TCGAã€scRNAã€scDNAã€scATACã€spatialã€spatiallyã€genomeã€transcriptomeã€proteomeã€Scanpyã€methylationã€histone
- ğŸ“ **æè¿°**ï¼šContributors : Trystan R Nadasen ; Ingo Hein ; Dave K BergerSeries Type : Expression profiling by high throughput sequencingOrganism : Cercospora zeina ; Zea maysCercospora zeina is a fungal pathogen that causes gray leaf spot (GLS) disease on maize (Zea mays L.) in South Africa. Upon landing on a maize leaf, the pathogen rapidly enters through the stomata and continues to develop asymptomatically for up to 28 days before symptoms are seen. As previous work has yet to adequately determine how the pathogen behaves during its infective period, we used transcriptomics to gain insights about the in-planta development of the pathogen and explore how it uses its effectors to facilitate this process. Samples from B73 maize inbreds infected with C. zeina were harvested in a time course experiment and used for RNA sequencing. We used reads mapped to the C. zeina genome as a proxy for biomass accumulation. At the end of the latent period, C. zeina was found to rapidly accumulate biomass and showed a nearly 50-fold increase in biomass as symptoms appeared. There were two distinct transcriptional waves occurring across the infection period. The first wave showed expression of genes for cellular growth, maintenance and immune avoidance, whereas the second wave was enriched with genes involved in detoxification and carbohydrate catabolism. A total of 140 putative effector genes were differentially expressed over the time-courses, with most up-regulated during the mid stage when the switch to necrotrophy occurs. Transient expression of three of these C. zeina effectors (CzEcp2, CzNis1a, CzNis1b) induced plant immunity in Nicotiana spp. resulting in the development of a hypersensitive response. This suggests that a cohort of C. zeina effectors expressed at this time have functions for which receptors have evolved in non-host species like tobacco. Altogether, this work suggests C. zeina behaves as a latent necrotroph during infection and provides a foundation for future research into the infection biology of C. zeina on maize.
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305815)

> ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 19 æ¡å†…å®¹ï¼Œè¯¦è§ [æ–‡æœ«](#æ›´å¤š-æ•°æ®å‰æ²¿)

</div>

</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (3æ¡)</summary>

<div class="details-content" markdown="1">

#### è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨3æ¡ï¼‰

**1.** â­ **QIAGENå°†æ”¶è´­Parse Biosciencesï¼Œä»è€Œå°†å…¶æ ·å“æŠ€æœ¯äº§å“ç»„åˆæ‰©å±•è‡³é«˜åº¦å¯æ‰©å±•çš„å•ç»†èƒè§£å†³æ–¹æ¡ˆé¢†åŸŸã€‚**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼štumorã€cancerã€oncologyã€TMEã€cardiacã€resistanceã€TCGAã€Hi-Cã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€spatialã€genomeã€genomicsã€Scanpyã€epigeneticã€methylationã€histone
- ğŸ“ **æè¿°**ï¼šQIAGENâ€™s acquisition of Parse Biosciences expands its RNA sequencing and single-cell analysis capabilities, fueling AI-powered drug discovery through scalable, instrument-free...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/qiagen-to-acquire-parse-biosciences-expanding-its-sample-technologies-portfolio-into-highly-scalable-single-cell-solutions/)

**2.** â­ **å•ç»†èƒRNAæµ‹åºæ­ç¤ºè—çŒªè„‚è‚ªç”Ÿæˆå’Œè„‚è‚ªé…¸è½¬è¿å¢å¼º**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€cardiacã€TCGAã€sequencingã€RNA-seqã€RNAseqã€DNA-seqã€ATAC-seqã€Hi-Cã€single.cellã€single-cellã€scRNAã€scDNAã€scATACã€Scanpyã€histone
- ğŸ“ **æè¿°**ï¼šUsing single-cell RNA sequencing, researchers uncovered enhanced adipogenesis and fatty acid transport in Tibetan pigs, explaining their superior fat accumulation and cold adaptation compared to Duroc pigs...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/enhanced-adipogenesis-and-fatty-acid-transport-in-tibetan-pigs-revealed-by-single-cell-rna-sequencing/)

**3.** â­ **é˜æ˜ä¸€ç§è°ƒèŠ‚éª¨éª¼ç”Ÿé•¿çš„æ–°æœºåˆ¶**
- âœï¸ **ä½œè€…**ï¼šæœªçŸ¥ä½œè€…
- ğŸ·ï¸ **å…³é”®è¯**ï¼šcancerã€immuneã€TMEã€TCGAã€histone
- ğŸ“ **æè¿°**ï¼šRNA sequencing revealed that Dnmt1 controls energy metabolism in growth plate chondrocytes, ensuring proper bone elongation and offering insight into bone growth disorders...
- ğŸ”— [æŸ¥çœ‹åŸæ–‡](https://www.rna-seqblog.com/elucidation-of-a-novel-mechanism-regulating-bone-growth/)


</div>

</details>

## ğŸ“Š å…³é”®è¯ç»Ÿè®¡

| å…³é”®è¯ | å‡ºç°æ¬¡æ•° |
|--------|----------|
| scRNA | 31 |
| TME | 30 |
| scATAC | 26 |
| genome | 26 |
| cancer | 25 |
| TCGA | 24 |
| scDNA | 24 |
| genomics | 21 |
| Seurat | 19 |
| glioma | 18 |
| cardiac | 14 |
| RNAseq | 13 |
| histone | 13 |
| tumor | 13 |
| single.cell | 12 |
| spatial | 12 |
| RNA-seq | 10 |
| single-cell | 9 |
| immune | 8 |
| Scanpy | 8 |

---

## ğŸ“ æ›´å¤šå†…å®¹

<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (10æ¡)</summary>

<div class="details-content" markdown="1">

- [è¿˜ä¸æ‡‚é™ç»´åˆ†æï¼ŸRtsneåŒ…ï¼Œè½»è½»æ¾æ¾å®ç°t-SNEå¯è§†åŒ–ï¼Œè®©ä½ å¿«é€ŸæŒæ¡é«˜ç»´æ•°æ®æ¢ç´¢ï¼](https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&mid=2247498460&idx=1&sn=694dc6011a345e9ea0623ccac5e1ea3c)
- [æœ€æ–°çš„33+æ–‡ç« ï¼Œè·¨å¾ªç¯ç³»ç»Ÿå’Œç»„ç»‡çš„æ³›ç™Œä»£è°¢åˆ†æï¼Œå˜Œå‘¤ä»£è°¢ä¹Ÿæ˜¯ç«èµ·æ¥äº†ï¼](https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&mid=2247503895&idx=1&sn=53e182448dcec2928f8ab1fb8df8bf07)
- [metasens åŒ…ï¼šå…·æœ‰ç¼ºå¤±æ•°æ®çš„äºŒå…ƒç»“å±€ metaåˆ†æä¸­çš„æ•æ„Ÿæ€§åˆ†æ](https://mp.weixin.qq.com/s?__biz=MzkzNzY2NDgyOQ==&mid=2247493115&idx=1&sn=71c44e2dfe1eb4af5f39c687306f7d4d)
- [åæ‚”ä»æ¹¿å®éªŒè½¬ç”Ÿä¿¡äº†ï¼ˆè™½ç„¶å·¥èµ„é«˜ä¸€ç‚¹ï¼‰](https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&mid=2247546783&idx=1&sn=aadf5fc53f09968197155a0edeb18b5c)
- [PRISM-GRNï¼šå•ç»†èƒå¤šç»„å­¦æ•°æ®ä¸­æ¢å¤åŸºå› è°ƒæ§ç½‘ç»œ](https://mp.weixin.qq.com/s?__biz=MzkyNDI1MzE0NA==&mid=2247490109&idx=1&sn=b1fae4019b23bba408c8733082faeeaa)
- [å¤§ç‰›è®¿è°ˆå½•ï¼šä¸¤å¤§æµ‹åºä»ªç¼”é€ è€…-Jonathan Rothberg](https://mp.weixin.qq.com/s?__biz=MzU3OTYwNjk1NA==&mid=2247523311&idx=1&sn=82732a8a9c07a1d1f4befb9f05b176f4)
- [11æœˆ22æ—¥è®ºå›æ—¥ç¨‹ | ç¬¬å…«å±Šä¸Šæµ·å›½é™…è‚¿ç˜¤å†…ç§‘å­¦è®ºå›ï¼ˆ8th SIMOSï¼‰å¤§å’–äº‘é›† é‚€æ‚¨ç›¸èš](https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&mid=2656509121&idx=2&sn=a0194415db33caca4971752533f9fe0f)
- [ä¸­å±±å¤§å­¦é™„å±ç¬¬å…«åŒ»é™¢å›¢é˜Ÿæœ€æ–°ç ”ç©¶ç™»ä¸Š Cancer Research å°é¢ï¼](https://mp.weixin.qq.com/s?__biz=MzUxMzk5MjY5NA==&mid=2247649656&idx=1&sn=fff6913c85a9ed234548bdfc10685e56)
- [å·¨å™¬ç»†èƒæåŒ–ä¸ä»£è°¢çš„äº¤äº’ä½œç”¨](https://mp.weixin.qq.com/s?__biz=MzkxOTI0Mjc3Mw==&mid=2247496586&idx=1&sn=08418cea9d4fb482236f6e3286591ac0)
- [ç»†èƒå›¾è°± | Nature | è·¨ç»„ç»‡å¤šç»†èƒåè°ƒåŠå…¶åœ¨ç™Œç—‡ä¸­çš„é‡æ„](https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&mid=2247502857&idx=1&sn=fdc3359d3edae0c4e4b2f10027d785d1)

</div>

</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (19æ¡)</summary>

<div class="details-content" markdown="1">

- [GSE279824 äººç±»è…ºæ ·ä½“å•ç»†èƒè½¬å½•ç»„åˆ†ææ­ç¤ºæ°”é“å¾®è¤¶çš±ç»†èƒçš„åˆ†å­ç‰¹å¾](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE279824)
- [GSE248477 åˆ©ç”¨ç‰›å®¿ä¸»è½¬å½•ç»„å­¦è¯„ä¼°å¸‚åœºå’Œç–«è‹—å¦‚ä½•å½±å“å¥åº·å’Œç–¾ç—…](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE248477)
- [GSE289792 æŠ‘åˆ¶å°èƒ¶è´¨ç»†èƒ SLC2A5 å¯å‡è½»æ€¥æ€§ç¼ºè¡€æ€§ä¸­é£åçš„è„‘æŸä¼¤ [RNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289792)
- [GSE289791 æŠ‘åˆ¶å°èƒ¶è´¨ç»†èƒ SLC2A5 å¯å‡è½»æ€¥æ€§ç¼ºè¡€æ€§ä¸­é£åçš„è„‘æŸä¼¤ [scRNA-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289791)
- [GSE217966 ç¼¬æ°¨é…¸é€šè¿‡æ”¹å˜å°é¼ è‡ªå™¬å’Œæ ¸é…¸ç”²åŸºåŒ–è¯±å¯¼ç¾ä¸¸ç»†èƒå‡‹äº¡](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE217966)
- [GSE297607 RhCMVæ‰©å¢CCR5è®°å¿†Tç»†èƒå¹¶ä¿ƒè¿›SIVåœ¨è‚ é“é»è†œä¸­çš„å‚¨å­˜åº“å½¢æˆ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE297607)
- [GSE276305 UMP ä½œä¸º NR4A1 çš„å†…æºæ€§è°ƒèŠ‚å› å­ï¼Œæ§åˆ¶èƒƒç™Œçš„è¿›å±• [ChIP-Seq]](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276305)
- [GSE141250ï¼š24-28å‘¨é¾„é‡ç”Ÿå‹å’ŒApoE-/-å°é¼ å¤–è†œå’Œä¸­è†œ/å†…è†œç»†èƒçš„å•ç»†èƒRNAæµ‹åº](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141250)
- [GSE292813 UGT2B17çš„éç»å…¸åŠŸèƒ½ä¿ƒè¿›å»åŠ¿æŠµæŠ—æ€§å‰åˆ—è…ºç™Œçš„è¿›å±•](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292813)
- [GSE140415 OncoScan CNV æ£€æµ‹ï¼ˆThermo Fisher Scientific/Affymetrixï¼‰æ•°æ®ï¼ŒåŒ…å« 13 ä¸ªå†·å‡é›†ç´ ç—…æ ·æœ¬](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140415)
- [GSE300036 è€å¹´å°é¼ ç™½è‰²è„‚è‚ªç»„ç»‡çš„å•ç»†èƒRNAæµ‹åºï¼ˆsc RNAseqï¼‰](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE300036)
- [GSE293218 ç§€ä¸½éšæ†çº¿è™«é•¿å¯¿å¹²é¢„çš„æœ‰æ•ˆæ€§å–å†³äºRNAå‰ªæ¥å› å­IIçš„æ—©æœŸç”Ÿå‘½æ´»æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE293218)
- [GSE292723 ç§€ä¸½éšæ†çº¿è™«é•¿å¯¿å¹²é¢„çš„æœ‰æ•ˆæ€§å–å†³äºRNAå‰ªæ¥å› å­çš„æ—©æœŸç”Ÿå‘½æ´»æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE292723)
- [GSE309530 RNA-seq åˆ†æï¼šéª¨æŠ˜æ‰‹æœ¯å’Œ Protectin DX æ²»ç–—åèƒŒæ ¹ç¥ç»èŠ‚ (DRG) çš„ RNA æµ‹åºè°±](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309530)
- [GSE263680 å—ä½“æ¿€é…¶å¼‚äºŒèšä½“ç²¾ç»†è°ƒæ§æ‹Ÿå—èŠ¥å½¢æˆå±‚æ´»æ€§](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263680)
- [GSE276294 UMPä½œä¸ºNR4A1çš„å†…æºæ€§è°ƒèŠ‚å› å­ï¼Œè°ƒæ§èƒƒç™Œçš„è¿›å±•](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE276294)
- [GSE286551 ç”²åŸº-CpGç»“åˆè›‹ç™½2æŠ‘åˆ¶cGASç›¸å…³ä¿¡å·ä¼ å¯¼](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286551)
- [GSE298388 é«“ç³» FABP5 å¯¹ç‚ç—‡æ€§ç–¼ç—›çš„è°ƒèŠ‚](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE298388)
- [GSE140534 äººç±»å°èƒ¶è´¨ç»†èƒçš„å­˜æ´»å› ç´ ](http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE140534)

</div>

</details>

---

*ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-08 21:35*  
*ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ*